BEDFORD, Ohio, Feb. 22 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., announced FDA approval to begin shipping Methylprednisolone Sodium Succinate for Injection, USP. This product is AP rated and is equivalent to Solu-Medrol(R) by Pfizer. Methylprednisolone is an adrenocorticosteriod hormone with multiple indications including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, gastrointestinal diseases, allergic states, ophthalmic diseases and neoplastic diseases.
“As part of our continuing strategy to expand our product portfolio, Bedford Laboratories is pleased to be offering such a widely demanded, and important product,” said David Gaugh, Vice President of Bedford Laboratories.
Bedford Laboratories will supply Methylprednisolone Sodium Succinate for Injection, USP as a sterile lyophilized powder in four single dose presentations: 40mg, 125mg, 500mg and 1gram.
Prescribing information is available upon request from the Bedford Laboratories’ professional services department, (800) 521-5169, or from the company’s web site, www.bedfordlabs.com.
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and approximately 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of US $11.8 billion (9.5 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information on Boehringer Ingelheim, please visit www.boehringer-ingelheim.com.
Bedford Laboratories
CONTACT: Jason Kurtz of Bedford Laboratories, +1-800-562-4797, Ext. 3668
